Eculizumab in the treatment of atypical hemolytic uremic syndrome in an infant leads to cessation of peritoneal dialysis and improvement of severe hypertension
- 488 Downloads
Severe hypertension (HTN) and acute kidney injury frequently associated with atypical hemolytic uremic syndrome (aHUS) were refractory to various therapies in the pre-eculizumab era. Here we report the case of a 4-month-old boy who developed aHUS presenting with undetectable C3 protein, no predisposing mutations in complement factors, and no antibodies against factor H.
Repeated plasma infusions and nine sessions of plasmapheresis were ineffective. The patient initially required continuous hemodiafiltration and thereafter peritoneal dialysis. Despite vigorous antihypertensive treatment and improved fluid overload with dialysis, HTN persisted. His low C3 level (<20 mg/dl) suggested unrestricted complement activation. Therefore, based on the suspicion of unrestricted complement cascade in the pathogenesis, treatment with eculizumab, a human anti-C5 monoclonal antibody, was initiated with the aim of controlling disease activity.
Eculizumab therapy resulted in the control of severe HTN and cessation of peritoneal dialysis.
This infant with HTN and acute kidney injury associated with aHUS was treated successfully with eculizumab.
KeywordsPlasmapheresis-resistant Meningococcal infection Prophylactic antibiotics Vaccination Pathological findings Atypical hemolytic uremic syndrome Anti-C5 therapy
We thank Dr. Camille L. Bedrosian of Alexion Pharmaceuticals Inc. for helpful comments and Alexion Pharmaceuticals Inc. for providing eculizumab (Soliris) without charge prior to the approval of the use of eculizumab for the treatment of aHUS by Health, Labor and Welfare Ministry in Japan. Medical writing support was provided by Dr. John Kincaid (Alexion Global Medical Affairs).
Conflict of interest
- 2.Ariceta G, Besbas N, Johnson S, Karpman D, Landau D, Licht C, Loirat C, Pecoraro C, Taylor CM, Van de Kar N, Vandewalle J, Zimmerhackl LB; European Paediatric Study Group for HUS (2009) Guideline for the investigation and initial therapy of diarrhea-negative-hemolytic uremic syndrome. Pediatr Nephrol 24:687–696Google Scholar
- 10.Ishikura K, Uemura O, Ito S, Wada N, Hattori M, Ohashi Y, Hamasaki Y, Tanaka R, Nakanishi K, Kaneko T, Honda M; Pediatric CKD Study Group; Japan Committee of Measures for Pediatric CKD of the Japanese Society of Pediatric Nephrology (2013) Pre-dialysis chronic kidney disease in children: results of a nationwide survey in Japan. Nephrol Dial Transplant 28:2345–2355Google Scholar
- 14.Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T (2013) Terminal complement inhibitor eculizumab in atypical hemolytic–uremic syndrome. N Eng J Med 368:2169–2181CrossRefGoogle Scholar
- 15.Fakhouri F, Hourmant M, Campistol JM, Catalana SR, Espinosa M, Gaber AO, Menne J, Minetti EE, Provot F, Rondeau E, Ruggenenti P, Weelers LE, Ogawa M, Bedrosian CL, Legendre CM (2013) Eculizumab inhibits thrombotic microangiopathy and improves renal function in adult atypical hemolytic uremic syndrome patients. J Am Soc Nephrol 24:49A–50AGoogle Scholar
- 16.Laszik Z (1996) Thrombotic microangiopathies. In: Silva F, D’Agati V, Nadasdy T (eds) Renal biopsy interpretation. Churchill Livingstone, New York, pp 283–308Google Scholar